Financings in Brief: Premier Laser
This article was originally published in The Gray Sheet
Premier Laser: Receives more than $20 mil. in proceeds from the exercise of publicly traded Class A and Class B warrants. To cover the exercise of 1.5 mil. Class A warrants and 1.3 mil. Class B warrants, Premier issues about 2.8 mil. shares of Class A common stock. Redemption of the warrants followed FDA's May 6 clearance of Premier's Centauri laser system for hard tissue dental applications ("The Gray Sheet" May 12, I&W-1). Proceeds will provide working capital to support "the ramp in manufacturing, inventory and deliveries," the firm says...
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.